All In Biotech

Drug Trial Radar · NCT06903286

Extension Study of Participants From SPG302-ALS-001

An Open-label Extension of SPG302-ALS-001 Study to Evaluate the Long-term Safety and Efficacy of Daily Oral SPG302 Treatment in Participants With Amyotrophic Lateral Sclerosis

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

16

Actual

Start

May 29, 2025

Primary completion

Jun 30, 2025

Study completion Aug 31, 2025

Sponsor

Lead sponsor
SpinogenixIndustry
Sponsor type
Industry
First posted
Mar 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • SPG302Drug

    Open label SPG302 to be self-administered daily by eligible participants for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent adverse events and serious adverse eventsTime frame: Up to 52 weeks
  2. C-SSRS (Columbia Suicide Severity Rating Scale)Time frame: Up to 52 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Macquarie University

    North Ryde, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Flinders Medical Center

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.